Cornerstone Therapeutics Inc. (NASDAQ:CRTX)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body's inflammatory response.

Results 1 - 15 of 15

Recs

0
Member Avatar mlmscooter (< 20) Submitted: 6/2/2013 10:13:28 AM : Outperform Start Price: $8.80 CRTX Score: -13.86

A+ in accumulation by institutions

Recs

2
Member Avatar zzlangerhans (99.80) Submitted: 9/12/2011 10:45:56 PM : Outperform Start Price: $6.49 CRTX Score: -26.77

My old college dorm was voted "Most apathetic" in a student survey, so we all got T-shirts that said "Everyone says we're apathetic, but we don't care." That's pretty much how I feel about Cornerstone. I care just enough to drop a green thumb and a pitch.

Cornerstone is a good candidate for a rebound if broad market parameters improve. Revenues have been stable and the bottom line will benefit from sales of Spectracef and Factive. Impending approval of generic Tussionex may provide another boost. CAPS only, 5-10 points and out.

Recs

0
Member Avatar bobsweet (< 20) Submitted: 3/18/2010 11:46:49 PM : Outperform Start Price: $5.60 CRTX Score: -1.00

If you really look indepth into this company then you would know it is poised to explode. Great forward P/E, P/S, P/Book while holding alot of cash with very little debt. 72.5% insider owned while still trading under 200M volume... Tom Gardner knows it and so should you. JUMP IN NOW!

Recs

0
Member Avatar or10n (< 20) Submitted: 1/22/2010 9:52:53 AM : Outperform Start Price: $5.15 CRTX Score: +5.20

trades below book value - generates revenue - solid prospects

Recs

1
Member Avatar 3domfighter (< 20) Submitted: 1/12/2010 8:52:52 PM : Outperform Start Price: $5.32 CRTX Score: +3.41

This profitable pharmaceutical company has a simple business model with less R&D expense than most. At $5.23/share it is trading at less than half it's 52 week high and below its 200-day moving average while continuing to increase revenues and profits. Did I mention it's trading below book value? It won't be long until the pack finds this one.

Recs

0
Member Avatar scoobamang (< 20) Submitted: 10/16/2009 2:04:24 PM : Outperform Start Price: $6.02 CRTX Score: -25.65

Good fundamentals in the pharmaceutical industry.

Recs

0
Member Avatar SmallPimpin (34.51) Submitted: 8/14/2009 5:44:06 PM : Outperform Start Price: $6.59 CRTX Score: -58.66

Mmm...pharmaceuticals...

Recs

0
Member Avatar targetphil (82.65) Submitted: 7/29/2009 10:29:33 PM : Outperform Start Price: $9.84 CRTX Score: -106.26

feelin FOOLISH!

Recs

0
Member Avatar sheltie101 (< 20) Submitted: 7/10/2009 10:42:05 PM : Outperform Start Price: $8.11 CRTX Score: -101.18

Asthma as a health problem is increasing and CRTX has solid offerings for treatment.

Recs

4
Member Avatar jegray88 (< 20) Submitted: 10/17/2007 12:16:21 PM : Outperform Start Price: $2.40 CRTX Score: +259.92

Recent gov't approval for a sustained release asthma medication. Young company partnering with older more stabilized companies to work on innovations in medicine.

Recs

1
Member Avatar romad829 (76.03) Submitted: 8/15/2007 8:47:14 PM : Outperform Start Price: $2.46 CRTX Score: +235.63

Will go up post fall season.

Recs

1
Member Avatar spikenailz (30.94) Submitted: 7/26/2007 10:42:05 AM : Outperform Start Price: $2.30 CRTX Score: +272.70

They have had huge success with their asthma meds and they have some new ones in late stages of trials. This company has no where to go but up.

Recs

0
Member Avatar kevinnail (< 20) Submitted: 7/26/2007 9:41:58 AM : Outperform Start Price: $2.31 CRTX Score: +270.72

They have some awesome asthma meds on the market and other stuff in the pipeline coming on board in the near future.

Recs

1
Member Avatar jupamc (< 20) Submitted: 6/19/2007 3:30:41 PM : Outperform Start Price: $2.36 CRTX Score: +265.08

Expect major revenue increases starting 2H07 due to increase of effective salesforce from 20 to 240 with Dey partnership and new reformulation of zileuton (ZyFlo CR). May see some earlier rev. uptick due to co-marketing started in Q2. New formulation is a feasible alternative advantage to Singulair, which some people are reporting, produces side effects such as depression, anxiety.

Recs

1
Member Avatar henncoop (89.65) Submitted: 5/16/2007 1:27:33 PM : Outperform Start Price: $2.35 CRTX Score: +264.04

new product or reformation of current product should be approved ..so more revenue

Results 1 - 15 of 15

Featured Broker Partners


Advertisement